Literature DB >> 1775520

Ritanserin reduces abuse of alcohol, cocaine, and fentanyl in rats.

T F Meert1, F Awouters, C J Niemegeers, K H Schellekens, P A Janssen.   

Abstract

Rats that had received 3% alcohol, 0.01% cocaine, or 0.002% fentanyl as the only beverage over 10 days showed marked preference for the drug solution when water was made available as a second fluid in a separate bottle. Treatment with low doses of ritanserin, a specific central serotonin 5-HT2 antagonist, rapidly reversed drug preference without changing total fluid intake. Quantitatively, the reduction in drug consumption was greater for alcohol than for cocaine and greater for cocaine than for fentanyl. This is probably related to differences in the reinforcing potential of the three drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1775520     DOI: 10.1055/s-2007-1014461

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

1.  Effects of ritanserin and chlordiazepoxide on sleep-wakefulness alterations in rats following chronic cocaine treatment.

Authors:  C Dugovic; T F Meert; D Ashton; G H Clincke
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Radioligands for brain 5-HT2 receptor imaging in vivo: why do we need them?

Authors:  G F Busatto
Journal:  Eur J Nucl Med       Date:  1996-08

3.  Potentiation of the effects of raclopride on sucrose consumption by the 5-HT2 antagonist ritanserin.

Authors:  A M Montgomery; A Suri
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 4.  Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  Ritanserin and voluntary alcohol intake in rats.

Authors:  T Rammsayer; W H Vogel
Journal:  Integr Physiol Behav Sci       Date:  1994 Oct-Dec

Review 6.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

Review 7.  A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.

Authors:  R B Rothman; J R Glowa
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

Review 8.  Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Authors:  Paul W Czoty; William W Stoops; Craig R Rush
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 9.  Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal.

Authors:  Tamzin L Ripley; David N Stephens
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

10.  Real time detection of acute (IP) cocaine-enhanced dopamine and serotonin release in ventrolateral nucleus accumbens of the behaving Norway rat.

Authors:  P A Broderick; E P Kornak; F Eng; R Wechsler
Journal:  Pharmacol Biochem Behav       Date:  1993-11       Impact factor: 3.533

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.